menu
    • menu
    [{"orgOrder":0,"company":"Arcellx","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"CART-ddBCMA","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Arcellx \/ Samsara BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Samsara BioCapital"},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ACLX-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Not Applicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"CART-ddBCMA","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CART-ddBCMA","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":4.2300000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.2300000000000004,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CART-ddBCMA","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Not Applicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CART-ddBCMA","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Not Applicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"ACLX-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Kite Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Arcellx

    Menu

    Arcellx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACLX-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Kite Pharma

                            Deal Size : $285.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Arcellx and Kite Announce Expansion in Strategic Partnership

                            Details : Under the expanded collaboration, Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA.

                            Brand Name : ACLX-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $85.0 million

                            November 15, 2023

                            Lead Product(s) : ACLX-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Kite Pharma

                            Deal Size : $285.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quart...

                            Details : CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma.

                            Brand Name : CART-ddBCMA

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 14, 2023

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arcellx Announces Clinical Hold for Its IMMagine-1 Phase 2 Clinical Program

                            Details : CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 19, 2023

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kite Pharma

                            Deal Size : $325.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multipl...

                            Details : Kite and Arcellx were jointly working to advance and commercialize the CART-ddBCMA asset for relapsed or refractory multiple myeloma in U.S., and Kite was supposed to commercialize outside the U.S.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $225.0 million

                            January 30, 2023

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kite Pharma

                            Deal Size : $325.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kite Pharma

                            Deal Size : $4225.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-...

                            Details : CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma. CART-ddBCMA utilizes Arcellx’s novel D-Domain binder.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $225.0 million

                            December 09, 2022

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kite Pharma

                            Deal Size : $4225.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACLX-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therape...

                            Details : ACLX-001, ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and overcome tumor heterogeneity.

                            Brand Name : ACLX-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 10, 2022

                            Lead Product(s) : ACLX-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcellx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Samsara BioCapital

                            Deal Size : $115.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Thera...

                            Details : The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022.

                            Brand Name : CART-ddBCMA

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 13, 2021

                            Lead Product(s) : CART-ddBCMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Samsara BioCapital

                            Deal Size : $115.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth